

## Treatment-Experienced

**TABLE 197: WITHDRAWALS — ALL-CAUSE(S)**

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Andreone et al., 2014 PEARL-II	1b	(14) PAR/RIT12 + OMB12 + DAS12	0	95	0%
Bacon et al., 2011 RESPOND2	1	(1) PR48	5	80	6%
		(74) B32 PR36-48 RGT	16	162	10%
Bourlière et al., 2015 SIRIUS	1	(7) SOF24 + LDV24	0	77	0%
		(10) SOF12 + LDV12 + RBV12	0	78	0%
Dieterich et al., 2014-2+3+4	1	(69) SIM12 PR24-48 RGT or SIM12 PR48	5	53	9%
Forns et al., 2015 C-SALVAGE	1	(23) GRZ12 + ELB12 + RBV12	2	79	3%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Gane et al., 2013-2 ELECTRON	1	(3) SOF12 + RBV12	0	10	0%
Gane et al., 2014-2 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	0	9	0%
Gane et al., 2014-3 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	0	9	0%
Forns et al., PROMISE (HPC3007)	1	(1) PR48	14	133	11%
		(42) SIM12 PR24-48 RGT	10	260	4%
Jacobson et al., 2013 FUSION	2+3	(3) SOF12 + RBV12	49	103	48%
Jensen et al., 2015-1 HALLMARK-QUAD	1+4	(18) DCV24 + ASU24 + PR24	1	354	0%
Jensen et al., 2015-2 HALLMARK-QUAD	1+4	(18) DCV24 + ASU24 + PR24	0	44	0%
Lawitz et al., 2014 LONESTAR	1	(6) SOF12 + LDV12	0	19	0%
		(10) SOF12 + LDV12 + RBV12	0	21	0%
Lawitz et al., 2014 COSMOS	1	(72) SOF12 + SIM12 + RBV12	0	27	0%
		(5) SIM12 + SOF12	0	14	0%
Manns et al., 2014 HALLMARK-DUAL	1b	(17) DCV24 + ASU24	0	205	0%
Mizokami et al. et al., 2015	1	(6) SOF12 + LDV12	0	88	0%
		(10) SOF12 + LDV12 + RBV12	0	87	0%
Molina et al., 2015 PHOTON-2	3	(4) SOF24 + RBV24	0	49	0%
Omata et al., 2014	2	(3) SOF12 + RBV12	0	63	0%
Osinusi et al., 2014 SYNERGY	1	(6) SOF12 + LDV12	0	14	0%
Pol et al., 2015	1	(40) SOF12 + PR12	0	80	0%
Reddy et al., 2015 ATTAIN	1	(39) T12 PR48 q8	29	384	8%
		(68) SIM12 PR48	21	379	6%
Sulkowski et al., 2014-3	3	(4) SOF24 + RBV24	2	17	12%
Wyles et al., 2015	1	(10) SOF12 + LDV12 + RBV12	0	51	0%
Zeuzem et al., 2011 REALIZE	1	(1) PR48	22	132	17%
		(39) T12 PR48 q8	21	266	8%
Zeuzem et al., 2014 ASPIRE	1	(1) PR48	7	66	11%
		(68) SIM12 PR48	5	66	8%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.